ArticleCancer discovery2013
Teaching an old dog new tricks: drug repositioning in small cell lung cancer.
Article in Cancer discovery, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 22 citations in OpenAlex.
- Review
- Repurposing non-oncology small-molecule drugs to improve cancer therapy: Current situation and future directions.Acta pharmaceutica Sinica. B · 2022Review
- Avasimibe exerts anticancer effects on human glioblastoma cells via inducing cell apoptosis and cell cycle arrest.Acta pharmacologica Sinica · 2021Article
- Impact of tricyclic antidepressants, selective serotonin reuptake inhibitors, and other antidepressants on overall survival of patients with advanced lung cancer from 2004 to 2014: University of Cincinnati experience.The Journal of international medical research · 2019Article
- Exploiting drug repositioning and the brain microenvironment to treat brain metastases.Neuro-oncology · 2016Article
- Small cell lung cancer: will recent progress lead to improved outcomes?Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Review
- Small cell lung cancer: where do we go from here?Cancer · 2015Review
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Jahchan and colleagues report the use of a biostatistical analysis to identify effective therapeutics for small cell lung cancer (SCLC). Their results reveal a new use for the tricyclic antidepressant imipramine in SCLC and shed light on the therapeutic potential of drug repositioning in cancer and other diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.